Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06383819
NCT06383819CompletedPhase 3

Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

NPO Petrovax30 sites in 1 country392 target enrollmentStarted: April 8, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
392
Locations
30
Primary Endpoint
Change in Forced vital capacity (FVC) (visit 4)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection

Detailed Description

The main objective of the clinical study was to prove the superiority of the efficacy of the drug Longidaza® over placebo when used in adult patients with residual changes in the lungs after COVID-19 infection based on the dynamics of respiratory function

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male and female patients aged 18 to 80 years, who signed an informed consent form.
  • •The condition after infection with COVID-19, documented in the period from 1 to 12 months before screening (ICD-10: U07.1, U07.2), including accompanied by hospitalization of the patient.
  • •The presence of a negative result of the polymerase chain reaction test (PCR) during screening and an express test for the SARS-CoV-2 antigen at visit
  • •The presence of respiratory symptoms (at least dyspnea), while the severity of dyspnea on the mMRC during screening is ≥ 1 point.
  • •The value of hemoglobin oxygen saturation: SpO2 < 95% at rest at the screening; and/or desaturation (decrease of SpO2 by ≥ 4% in the 6MWT relative to the value at rest) at the screening.
  • •The presence of residual changes in the lung parenchyma characteristic of previous COVID-19 infection, > 10% of the area, according to CT at the screening
  • •Respiratory dysfunction of the restrictive type at the screening: FVC < 80%, FVC 1 / FVC > 70%.

Exclusion Criteria

  • •A history of chronic respiratory diseases (interstitial lung disease, chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, lung cancer).
  • •Clinical signs or anamnesis data on the presence of diseases that, according to the researcher, can lead to restrictive changes in respiratory function (pronounced kyphoscoliosis, pleural effusion, neuromuscular diseases), pathological obesity, etc.
  • •Clinical signs or anamnesis data on the presence of unstable angina pectoris, stable angina pectoris of high functional class, clinically significant cardiac arrhythmias, chronic heart failure, pulmonary hypertension, suffered pulmonary embolism or acute myocardial infarction in within 6 months prior to screening.
  • •Dyspnea of any other etiology: thyrotoxicosis, anemia (hemoglobin less than 100 g/l), pathological obesity (BMI ≥ 40 kg/m2), metabolic acidosis, neuromuscular diseases according to anamnesis or screening examination.
  • •The presence of an acute infectious process of any etiology and localization.
  • •Allergic reactions to the administration of azoximer bovhyaluronidase or an auxiliary component of the studied drug (mannitol) in the anamnesis.
  • •Clinical signs of pulmonary hemorrhage and/or hemoptysis during examination and in the anamnesis.
  • •Confirmed eye injuries with vitreous hemorrhage during the last 6 months according to the medical history.
  • •Malignant neoplasms of any localization in the anamnesis, with the exception of in situ carcinoma, which required only surgical treatment.
  • •Renal failure.
  • •Taking drugs of prohibited therapy since the start of screening in this study.
  • •Serological test positive for HIV infection, viral hepatitis B and C.
  • •Pregnancy or breastfeeding.
  • •Participation in clinical trials of an experimental drug within 30 days prior to screening for participation in the current study.
  • •Any other medical or social conditions that, in the opinion of the research physician, do not allow the patient to participate in this study.

Arms & Interventions

Longidaza®

Experimental

Bovhyaluronidase azoximer, 3000 IU

Intervention: Longidaza® (Drug)

Placebo

Placebo Comparator

The placebo will contain no active pharmaceutical ingredients.

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Change in Forced vital capacity (FVC) (visit 4)

Time Frame: Baseline to Day 71±1

Change in the FVC (%) compared with the initial data according to spirometry data after completion of the course of therapy

Secondary Outcomes

  • Dynamics of hemoglobin oxygen saturation (SpO2)(Baseline, Day 71±1, Day 180±3)
  • The proportion of patients with SpO2 ≥ 93% and < 93%(Baseline, Day 71±1, Day 180±3)
  • Change in FVC (visit 5)(Baseline to Day 180±3)
  • The proportion of patients with desaturation(Baseline, Day 71±1, Day 180±3)
  • Slowing the decline in respiratory function(Baseline to Day 180±3)
  • The proportion of patients with an increase in the FVC (%)(Baseline, Day 71±1, Day 180±3)
  • The proportion of patients with an increase in the distance of 6MWT(Baseline, Day 71±1, Day 180±3)
  • The proportion of patients with a decrease in the severity of dyspnea on the Borg scale(Baseline, Day 71±1, Day 180±3)
  • The proportion of patients with a decrease in the severity of dyspnea on the Modified Medical Research Council Dyspnea Scale (mMRC)(Baseline, Day 71±1, Day 180±3)
  • Change in the assessment of the quality of life according to the European Quality of Life 5-Dimension 5-Level Questionnaire (EuroQol-5D-5L)(Baseline, Day 71±1, Day 180±3)
  • Change in cough severity on the Visual Analogue Scale (VAS)(Baseline, Day 71±1, Day 180±3)

Investigators

Sponsor
NPO Petrovax
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (30)

Loading locations...

Similar Trials

Completed
Not Applicable
Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic HyperplasiaLower Urinary Tract SymptomsProstatic Hyperplasia
NCT06568718NPO Petrovax229
Unknown
Not Applicable
Study of the Efficacy and Safety of Longidaze® for the Treatment of Patients With External Genital EndometriosisExternal Genital Endometriosis
NCT04962620NPO Petrovax149
Completed
Phase 2
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)Chronic Spontaneous Urticaria
NCT03437278Novartis Pharmaceuticals49
Completed
Phase 2
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and CirrhosisLiver FibrosisLiver Cirrhosis
NCT00956098HK inno.N Corporation81
Completed
Phase 3
Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous InfusionParkinson's Disease
NCT00408915Axxonis Pharma AG60